These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 31983188)
1. Immunohistochemical Expression of Programmed Death Ligand-1 (PDL-1) in Colorectal carcinoma and Its Correlation with Stromal Tumor Infiltrating Lymphocytes. Elfishawy M; Abd-ELaziz SA; Hegazy A; El-Yasergy DF Asian Pac J Cancer Prev; 2020 Jan; 21(1):225-232. PubMed ID: 31983188 [TBL] [Abstract][Full Text] [Related]
2. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168 [TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968 [TBL] [Abstract][Full Text] [Related]
4. PD-L1 Expression in colorectal carcinoma and its correlation with clinicopathological parameters, microsatellite instability and BRAF mutation. Srivastava P; Husain N; Shukla S; Chauhan S; Pandey A; Masood S Indian J Pathol Microbiol; 2021; 64(3):490-496. PubMed ID: 34341259 [TBL] [Abstract][Full Text] [Related]
5. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323 [TBL] [Abstract][Full Text] [Related]
6. PD-L1 Immunohistochemical Expression in Endometrial Carcinoma: Egyptian Cross-Sectional Study. Wahba MG; Soliman SS; Salama ME; Nasr S; Al Shereef ZAE Asian Pac J Cancer Prev; 2024 Apr; 25(4):1441-1450. PubMed ID: 38680006 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915 [TBL] [Abstract][Full Text] [Related]
9. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer. Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649 [TBL] [Abstract][Full Text] [Related]
10. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene. Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of tumor PD-L1 expression combined with CD8 Wang Q; Lou W; Di W; Wu X Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors. Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013 [TBL] [Abstract][Full Text] [Related]
13. The Immunoscore is a Superior Prognostic Tool in Stages II and III Colorectal Cancer and is Significantly Correlated with Programmed Death-Ligand 1 (PD-L1) Expression on Tumor-Infiltrating Mononuclear Cells. Yomoda T; Sudo T; Kawahara A; Shigaki T; Shimomura S; Tajiri K; Nagasu S; Fujita F; Kinugasa T; Akagi Y Ann Surg Oncol; 2019 Feb; 26(2):415-424. PubMed ID: 30569297 [TBL] [Abstract][Full Text] [Related]
14. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients. El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185 [TBL] [Abstract][Full Text] [Related]
15. Expression of programmed death ligand-1 (PD-L1) and tumor infiltrating lymphocytes (TILs) in breast carcinoma and their clinical significance. Mondal SK; Bhattacharya S; Sarkar AP; Saha R J Cancer Res Ther; 2023 Apr; 19(Supplement):S81-S86. PubMed ID: 37147987 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study. Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma. Liu P; Xiao Q; Zhou B; Dai Z; Kang Y World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer. Ko YS; Pyo JS Int J Biol Markers; 2019 Jun; 34(2):132-138. PubMed ID: 30852949 [TBL] [Abstract][Full Text] [Related]
19. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737 [TBL] [Abstract][Full Text] [Related]
20. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC). Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]